Genetic Engineering Market Size, Share and Trends 2025 to 2034

Genetic Engineering Market Size and Forecast 2025 to 2034

The global genetic engineering market size was calculated at USD 1.62 billion in 2024 and is predicted to increase from USD 1.72 billion in 2025 to approximately USD 2.94 billion by 2034, expanding at a CAGR of 6.15% from 2025 to 2034. The growth of the market is driven by increasing government grants and funding to biotech startups. The rising production of vaccines and biologics further contributes to market growth.

Genetic Engineering Market Key Takeaways

• North America dominated the global market with the largest market share around 41% in 2024.
• Asia Pacific is expected to witness the fastest growth during the forecast period.
• By product, the genetic markers segment dominated the market in 2024.
• By product, the biochemical segment is expected to grow at a significant CAGR in the coming years.
• By device, the PCR segment led the market in 2024.
• By device, the gene gun segment is anticipated to expand at the fastest CAGR during the projection period.
• By technique, the gene splicing segment held the biggest share of the market in 2024.
• By technique, the artificial selection segment is projected to grow at the fastest CAGR in the upcoming period.
• By application, the medical industry segment held the major market share in 2024.
• By application, the agriculture segment is likely to expand at a rapid pace between 2025 and 2034.

Role of AI in Genetic Engineering

Artificial intelligence (AI) plays a crucial role in genetic engineering, driving innovations in various aspects. AI technology uses sophisticated computational processes to interpret and analyze genetic data. By accurately interpreting genetic data, AI technology provides academics and medical professionals with a greater understanding of the complex functions of the genome. This further improves the reliability and accuracy of genetic processes, which are central to the modern diagnosis and management of different health conditions. AI algorithms are also used to analyze vast datasets of genetic information, identify potential drug targets, and design novel therapies.

U.S. Genetic Engineering Market Size and Growth 2025 to 2034

The U.S. genetic engineering market size was exhibited at USD 464.94 million in 2024 and is projected to be worth around USD 860.17 million by 2034, growing at a CAGR of 6.35% from 2025 to 2034.

North America dominated the genetic engineering market in 2024 by capturing the largest share. This is mainly due to the increased government funding in research and development of genetic engineering. A large pool of skilled researchers and a robust research infrastructure further bolstered the market in the region. Increasing healthcare innovations, advances in healthcare technology, and increasing prevalence of chronic and genetic diseases further bolstered the market. The U.S. is a major contributor to the North American genetic engineering market. The strong presence of major bioscience companies such as eGenesis, Intellia Therapeutics, Editas Medicine, Caribou Biosciences, Synthego, and Inari further support the growth of the market. There is a high demand for personalized medicines.

• In December 2024, NewBiologix, a technology innovation company pioneering efficient, cost-effective, and scalable production of viral vectors for gene and cell therapy, announced the launch of its new U.S. subsidiary.

Asia Pacific is projected to witness the fastest growth during the forecast period, driven by escalating government investments in biotechnology research and the increasing demand for biologics. With the growing prevalence of chronic diseases, there is a high demand for gene therapies. Rising healthcare expenditure and favorable government policies contribute to the market's expansion. China is expected to have a stronghold on the Asia Pacific genetic engineering market. The rising investments in R&D activities drive market growth. In China, CRISPR/Cas gene-editing technology is transforming the crop breeding sector due to its simplicity, speed, and precision in generating the necessary genetic mutations for crop development.

Europe is projected to grow significantly during the forecast period due to advancements in biotechnology. Increasing awareness of early disease detection is boosting the demand for genetic testing. The region is at the forefront of healthcare and biotech innovations. The rising funding programs for R&D activities support regional market growth.

Market Overview

Genetic engineering is quickly modernizing fields such as medicine, agriculture, and biotechnology, accelerating the production of gene therapies, vaccines, and disease-resistant crops. Progression in high-throughput sequencing processes enabled the development of robust technology for quantitatively measuring the transcriptome, the expressed genes in a sample. The genetic engineering market is witnessing rapid growth due to the rising demand for personalized medicines. Genetic engineering is increasingly used in agriculture to improve crop yield and nutrient content. Synthetic biology is growing beyond modifying existing organisms to constructing and designing wholly new biologics. However, genetic engineering permits scientists to simulate biologics and predict results before experimental operation. The rising research and development activities focusing on genetic engineering and the increasing demand for gene therapies further contribute to market expansion.

Genetic Engineering Market Growth Factors

• The increasing interest in de-extinction, also known as resurrection biology, which revives extinct species of animals and plants by using biology is expected to boost the growth of the market in the coming years. Genome editing, cloning, and back-breeding are species restoration technology. This technology re-establishes dynamic processes that produce or restore extinct species, supporting ecosystems.
• Advancements in gene editing technologies are revolutionizing genetic engineering. Recent advances in biotechnology have expanded the scope of the application of genetic engineering in the industrial and agriculture sectors. 
• Increasing trends of synthetic biology further support market growth. Synthetic biology provides a novel approach for biological parts and systems or redesigning existing biological systems.
• The rising demand for personalized medicine boosts the growth of the market. Genetic engineering plays a key role in the development of personalized medicine.

Market Scope

Market Dynamics

Drivers

Expanding Applications of Genetic Engineering in Climate Resilient Agriculture

The rising impact of environmental change on global food security has accelerated research and investments in gene editing applications for crop and livestock enhancement, acting as a major driver for the genetic engineering market. Emerging genome editing initiatives are focused on increasing drought, heat, and salt tolerance in staple crops, such as maize and rice, with advancements already leading to the development of high-yield, climate-resilient rice varieties. These innovations enable the creation of cultivars that are not only more resistant to environmental stress but also promote sustainability by reducing input needs and improving productivity. Additionally, gene editing holds noteworthy potential in advancing livestock genetics for enhanced disease resistance and adaptability to changing climatic conditions. Genome editing plays a critical role in driving sustainable agriculture as agricultural stakeholders progressively adopt precision biotechnology solutions to address food system susceptibilities.

Restraint

Intellectual Property Complexities

Intellectual property surrounding genetic technologies, especially gene-editing platforms such as CRISPR, restrain the growth of the genetic engineering market. The intricate and often contentious patent landscape raises concerns related to access, affordability, and the equitable distribution of benefits from these transformative technologies. Disputes over ownership and licensing rights can create legal uncertainty, increase development costs, and hamper the ability of smaller organizations. Moreover, ethical concerns surrounding genetic modification, particularly in human applications, limit the growth of the market.

Opportunity

Advancements in Neuroinflammation-Targeted Gene Therapies

Gene therapy is rapidly emerging as a transformative therapeutic platform, providing the ability to deliver functional genetic material directly to cells to correct underlying genetic defects with potentially long-lasting effects from a single administration. Recent innovations in gene therapy strategies, predominantly those targeting neuroinflammation pathways in neurodegenerative diseases (NDs), are creating novel opportunities within the genetic engineering market. These approaches include the delivery of functional genes, RNA interference to silence mutant alleles, and disease-modifying interventions using gene-editing technologies. By addressing the root causes of neuroinflammatory responses in conditions like Alzheimer's and Parkinson's diseases, these novel gene therapy strategies not only solve a new class of treatments for complex central nervous system disorders but also position genetic engineering as a critical enabler of next-generation neurology solutions.

Product Insights

The genetic markers segment dominated the genetic engineering market with the largest share in 2024. Genetic markers are beneficial for the analysis of crop genomes, making them a significant tool in plant breeding. These markers are a small sequence of DNA that describes a specific trait. Genetic markers help to link hereditary disease with the responsible gene. The rise in the demand for genetic crops and precision medicine bolstered the segment.

The biochemical segment is expected to grow at a significant rate in the coming years. Biochemicals find applications in different sectors, from medicine and agriculture to environmental preservation and manufacturing. Biochemicals offer resistance against viruses, herbicides, and insects. They enhance the crops’ tolerance to high salinity levels in soil and enhance nutritional content. Biochemicals contribute to increasing production processes, improving the quality of products, and ensuring the nutritious value of food products.

Device Insights

The PCR segment held the largest share of the genetic engineering market in 2024. Polymerase chain reaction (PCR) enables the manipulation and analysis of genes, making it a preferred choice in laboratory settings. Its unique characteristics, like more sensitivity, enable us to detect smaller quantities of targeted DNA than many other testing processes. This makes it an ideal tool for identifying viruses and other pathogens in a sample that is present at very low concentrations. PCR tests permit the rapid and sensitive detection of particular nucleic acid sequences. They are broadly used in a variety of applications, including the diagnosis of communicable diseases.

The gene gun segment is anticipated to expand at the fastest rate during the projection period. Gene guns are widely used in genetic engineering to introduce RNA, DNA, or proteins into cells. These devices are easy to use, fast, and versatile, transferring large DNA fragments as well as small interfering RNA (siRNA) for gene silencing and transfecting many cell types, including non-dividing cells and plant cells.

Technique Insights

The gene splicing segment led the genetic engineering market with the largest share in 2024. This is mainly due to the rise in the demand for gene therapies. Gene splicing plays a key role in gene therapy to correct genetic defects and develop new treatments for diseases. Gene splicing allows a single gene to surge its capability of coding, enabling the synthesis of protein isoforms that are functionally and structurally distinct. Gene splicing is used to create a high proportion of genes.

The artificial selection segment is projected to grow at the fastest rate in the upcoming period as it enhances the speed and advances in genetic engineering to meet requirements and produce organisms with preferred traits. This technique is widely applied to a range of traits, from yield and disease resistance to stress tolerance and nutrient content. This technique allows for the analysis of border ranges of genetic variation that are found in nature. The increased need for sustainable and climate-resilient agriculture drives the growth of the segment.

Application Insights

The medical industry segment dominated the market in 2024. Genetic engineering is heavily used in the medical sector to mass-produce insulin, human growth hormones, vaccines, antihemophilic factors, monoclonal antibodies, human albumin, and other drugs. Genetic engineering allows researchers to improve the production of medicinal compounds by engineering the host organisms for greater yields and higher purity. With the increasing prevalence of chronic diseases, the demand for precision medicine has increased, in which genetic engineering is essential. Moreover, the rise in government investments in novel drug discovery and development bolstered segment growth.

The agriculture segment is likely to expand at a rapid pace in the coming years. The growth of the segment can be attributed to the rising demand for genetically modified crops. Genetic engineering is used in agriculture to improve crop yields, nutrient content, and disease resistance. The rising concerns about food safety further boost segmental growth.

Genetic Engineering Market Companies

• Thermo Fisher Scientific Inc.
• Lonza
• Cibus
• Recombinetics Inc.
• Sangamo
• Merck KGaA
• Precision Biosciences
• OriGene Technologies Inc.
• Intellia Therapeutics Inc.
• Caribou Biosciences Inc. 

Industry Leader Announcement

• In April 2025, SOHM, Inc., a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, announced the formation of a dedicated AI team focused on enhancing the capabilities of the ABBIE system and the design of novel guide RNAs and other RNA-guided integrase fusion proteins. This strategic initiative is set to further SOHM's mission of revolutionizing genome editing and cell engineering technologies and expanding the frontiers of genetic research. Dr. David Aguilar, COO of SOHM Inc., said, "By harnessing the power of AI, we aim to accelerate our research and development processes, ultimately leading to more effective and targeted genome editing solutions.”

Recent Developments in the Market

• In January 2025, EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, announced the launch of XDel Knockout Cells, an innovative product designed to transform the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results, which accelerate research in functional genomics, drug development, and disease modeling.
• In January 2025, MaxCyte, Inc., a leading cell-engineering-focused company providing solutions to advance the discovery, development, and commercialization of next-generation cell therapeutics, announced the acquisition of SeQure Dx, a market leader of on-target and off-target editing assessment services for cell and gene therapies.
• In January 2025, Genethon, a pioneer and leader in the research and development of gene therapies for rare diseases, and Eukarÿs, a biotechnology company developing a disruptive technology that significantly increases biomanufacturing yields, entered into a strategic partnership. The partnership aims to reduce the production costs of gene therapy medicines by harnessing Eukarÿs’ proprietary C3P3 technology, an innovative messenger RNA (mRNA) expression system in mammalian cells.
• In September 2023, SOHM, Inc., a pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors.

Segments Covered in the Report

By Product

• Biochemical
• Genetic Markers 

By Device

• PCR
• Gene Gun
• Gel Assemblies 

By Technique

• Artificial Selection
• Gene Splicing 

By Application

• Medical Industry
• Agriculture

By Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America